vs
Side-by-side financial comparison of Limbach Holdings, Inc. (LMB) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Limbach Holdings, Inc. is the larger business by last-quarter revenue ($186.9M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). Limbach Holdings, Inc. runs the higher net margin — 6.6% vs 1.6%, a 4.9% gap on every dollar of revenue. On growth, Limbach Holdings, Inc. posted the faster year-over-year revenue change (30.1% vs 5.0%). Over the past eight quarters, Limbach Holdings, Inc.'s revenue compounded faster (25.3% CAGR vs -0.2%).
Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LMB vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $186.9M | $177.4M |
| Net Profit | $12.3M | $2.9M |
| Gross Margin | 25.7% | — |
| Operating Margin | 9.4% | 3.9% |
| Net Margin | 6.6% | 1.6% |
| Revenue YoY | 30.1% | 5.0% |
| Net Profit YoY | 25.0% | — |
| EPS (diluted) | $1.01 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $186.9M | $196.9M | ||
| Q3 25 | $184.6M | $179.5M | ||
| Q2 25 | $142.2M | $181.1M | ||
| Q1 25 | $133.1M | $168.9M | ||
| Q4 24 | $143.7M | $187.3M | ||
| Q3 24 | $133.9M | $168.6M | ||
| Q2 24 | $122.2M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $12.3M | — | ||
| Q3 25 | $8.8M | $5.4M | ||
| Q2 25 | $7.8M | $-4.8M | ||
| Q1 25 | $10.2M | $4.8M | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | $7.5M | $-143.5M | ||
| Q2 24 | $6.0M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 25.7% | 79.5% | ||
| Q3 25 | 24.2% | 80.9% | ||
| Q2 25 | 28.0% | 77.4% | ||
| Q1 25 | 27.6% | 79.7% | ||
| Q4 24 | 30.3% | 78.7% | ||
| Q3 24 | 27.0% | 76.9% | ||
| Q2 24 | 27.4% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 9.4% | 1.2% | ||
| Q3 25 | 7.2% | 3.5% | ||
| Q2 25 | 7.5% | 4.7% | ||
| Q1 25 | 5.9% | 1.2% | ||
| Q4 24 | 9.1% | 13.2% | ||
| Q3 24 | 8.1% | -82.8% | ||
| Q2 24 | 6.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 4.8% | 3.0% | ||
| Q2 25 | 5.5% | -2.7% | ||
| Q1 25 | 7.7% | 2.8% | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 5.6% | -85.1% | ||
| Q2 24 | 4.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $1.01 | $0.05 | ||
| Q3 25 | $0.73 | $0.12 | ||
| Q2 25 | $0.64 | $-0.11 | ||
| Q1 25 | $0.85 | $0.10 | ||
| Q4 24 | $0.81 | $0.38 | ||
| Q3 24 | $0.62 | $-3.11 | ||
| Q2 24 | $0.50 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.3M | $144.3M |
| Total DebtLower is stronger | $30.5M | — |
| Stockholders' EquityBook value | $195.7M | $653.9M |
| Total Assets | $381.1M | $1.2B |
| Debt / EquityLower = less leverage | 0.16× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $11.3M | $238.4M | ||
| Q3 25 | $9.8M | $246.3M | ||
| Q2 25 | $38.9M | $445.9M | ||
| Q1 25 | $38.1M | $493.6M | ||
| Q4 24 | $44.9M | $484.6M | ||
| Q3 24 | $51.2M | $453.8M | ||
| Q2 24 | $59.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $30.5M | $372.2M | ||
| Q3 25 | $56.3M | $376.7M | ||
| Q2 25 | $28.4M | $580.5M | ||
| Q1 25 | $23.7M | $583.4M | ||
| Q4 24 | $23.6M | $585.3M | ||
| Q3 24 | $20.5M | — | ||
| Q2 24 | $19.7M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $195.7M | $693.1M | ||
| Q3 25 | $181.6M | $727.2M | ||
| Q2 25 | $170.5M | $757.8M | ||
| Q1 25 | $161.1M | $798.5M | ||
| Q4 24 | $153.5M | $778.3M | ||
| Q3 24 | $142.2M | $749.6M | ||
| Q2 24 | $133.0M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $381.1M | $1.3B | ||
| Q3 25 | $409.1M | $1.3B | ||
| Q2 25 | $343.0M | $1.5B | ||
| Q1 25 | $336.4M | $1.6B | ||
| Q4 24 | $352.1M | $1.6B | ||
| Q3 24 | $324.4M | $1.5B | ||
| Q2 24 | $303.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.16× | 0.54× | ||
| Q3 25 | 0.31× | 0.52× | ||
| Q2 25 | 0.17× | 0.77× | ||
| Q1 25 | 0.15× | 0.73× | ||
| Q4 24 | 0.15× | 0.75× | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.1M | — |
| Free Cash FlowOCF − Capex | $27.9M | — |
| FCF MarginFCF / Revenue | 14.9% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 2.29× | — |
| TTM Free Cash FlowTrailing 4 quarters | $41.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.1M | $43.7M | ||
| Q3 25 | $13.3M | $60.8M | ||
| Q2 25 | $2.0M | $12.0M | ||
| Q1 25 | $2.2M | $35.5M | ||
| Q4 24 | $19.3M | $33.1M | ||
| Q3 24 | $4.9M | $53.9M | ||
| Q2 24 | $16.5M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $27.9M | $43.5M | ||
| Q3 25 | $12.8M | $57.0M | ||
| Q2 25 | $1.2M | $9.3M | ||
| Q1 25 | $11.0K | $26.9M | ||
| Q4 24 | $18.0M | $31.0M | ||
| Q3 24 | $4.6M | $49.8M | ||
| Q2 24 | $13.2M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 14.9% | 22.1% | ||
| Q3 25 | 7.0% | 31.7% | ||
| Q2 25 | 0.8% | 5.1% | ||
| Q1 25 | 0.0% | 15.9% | ||
| Q4 24 | 12.5% | 16.6% | ||
| Q3 24 | 3.4% | 29.6% | ||
| Q2 24 | 10.8% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.3% | 2.2% | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 1.7% | 5.1% | ||
| Q4 24 | 0.9% | 1.1% | ||
| Q3 24 | 0.3% | 2.4% | ||
| Q2 24 | 2.7% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.29× | — | ||
| Q3 25 | 1.52× | 11.20× | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | 0.22× | 7.37× | ||
| Q4 24 | 1.96× | — | ||
| Q3 24 | 0.66× | — | ||
| Q2 24 | 2.77× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LMB
| Owner Direct Relationships Segment | $145.0M | 78% |
| General Contractor Construction Manager Relationships Segment | $41.9M | 22% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
